Survodutide

This randomized, double-blind, placebo-controlled dose-finding Phase 2 trial enrolled 387 adults with body mass index ≥27 without type 2 diabetes. Participants were assigned to once-weekly subcutaneous survodutide (target maintenance doses 0.6, 2.4, 3.6, or 4.8 mg) or placebo for 46 weeks following a titration period. Mean percentage body-weight reduction at week 46 was up to -14.9% across active arms versus -2.8% with placebo, with completers in the 4.8 mg arm achieving a mean reduction of -18.7%. Secondary endpoints — including the proportion achieving ≥5%, ≥10%, and ≥15% weight reduction — favored survodutide. Adverse events were predominantly gastrointestinal and consistent with the incretin pharmacology class profile.

Researchers ran a 46-week study comparing weekly survodutide injections at several doses to placebo in nearly 400 adults with overweight or obesity (without diabetes). Average weight loss reached about 15% on survodutide and roughly 19% in the highest-dose group who completed the trial, compared with about 3% on placebo. Side effects were mainly stomach-related (nausea, vomiting, diarrhea), which is typical for this class of molecule.

This Phase 2, randomized, double-blind, placebo-controlled trial evaluated weekly subcutaneous survodutide in 295 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F1–F3. Participants were assigned to survodutide (target maintenance doses 2.4, 4.8, or 6.0 mg) or placebo for 48 weeks. The primary endpoint — histological improvement of MASH without worsening of fibrosis — was achieved by up to 83% of participants in pooled survodutide arms versus 18% with placebo. Secondary endpoints showed reductions in liver fat content of ≥30% in 63–67% of survodutide-treated participants and improvement in fibrosis by ≥1 stage in 34–36% versus 22% with placebo. Adverse events were predominantly gastrointestinal.

A 48-week study tested weekly survodutide in about 300 adults with MASH (a liver condition involving fat, inflammation, and scarring). Up to 83% of participants on survodutide showed improvement in MASH on biopsy without their fibrosis getting worse, compared with 18% on placebo. Liver fat dropped substantially in most participants in the active arms, and a meaningful share also showed improvement in fibrosis. Side effects were mostly gastrointestinal.